Tianjin Tianyao Pharmaceuticals (600488.SH) announced that the company received notification from the Brazilian Health Regulatory Agency (referred to as "ANVISA...")
According to the Zhituo Finance APP, Tianjin Tianyao Pharmaceuticals (600488.SH) announced that the company received a approval notification from Brazil's Health Regulatory Agency (referred to as "Brazil ANVISA") for the Active Pharmaceutical Ingredient Dexamethasone Phosphate Sodium. Dexamethasone Phosphate Sodium has anti-inflammatory, anti-allergic, anti-rheumatic, and immunosuppressive effects, and is commonly used for allergic and autoimmune diseases. The company submitted the registration application for Dexamethasone Phosphate Sodium to Brazil ANVISA in March 2023 and recently received approval.
The approval of the Active Pharmaceutical Ingredient Dexamethasone Phosphate Sodium by Brazil ANVISA signifies that the company can meet the needs of related formulation clients, which will positively impact the company's expansion into the Brazilian market and enhance performance.